cropper
Pulse On Wellcare
  • Home
  • Categories
    • Healthcare
    • Trends
    • Insights
    • Southwest
    • Strategies
    • Prevention
    • Lifestyle
    • Mental Health
    • Preventative Care
    • Nutrition & Meal Planning
    • Telemedicine Access
    • Workplace Wellness
    • Wellness Tips
  • Events
  • Healthy Aging
November 22.2026
2 Minutes Read

Green Lumber Recalls Capsules Containing Hidden Tadalafil: Know the Risks

Green Lumber Recalls Capsules Containing Undisclosed Tadalafil, Citing Dangerous Heart-Medicine Interactions

The Major Recall of Green Lumber Capsules: What You Need to Know

Green Lumber Holdings is facing a significant recall of its Green Lumber Natural Fuel For Men capsules after they were found to contain tadalafil, the active ingredient in the prescription erectile dysfunction medication, Cialis. This alarming discovery was announced in a recall notice issued on November 19, and it has raised serious safety concerns, particularly regarding heart health. The lot being recalled is known as GL01, which has an expiration date of 09/27.

Potentially Life-Threatening Interactions

What makes this recall particularly concerning is the potential for tadalafil to interact dangerously with nitrates. Many older men who take these capsules may also be prescribed heart medications that contain nitrates, which can lead to a sudden and severe drop in blood pressure when combined with tadalafil. The FDA has cautioned that such interactions may cause dizziness, fainting, rapid heartbeat, or even serious cardiovascular events, such as heart attacks or strokes. Tadalafil's longer duration in the body further complicates this risk, as its effects can linger beyond the initial intake period.

A Troubling History

This situation is not an isolated incident for Green Lumber. The FDA first raised concerns about hidden tadalafil in Green Lumber products back in September 2019. The company previously issued a recall for six lots due to similar issues. In August 2025, the FDA found tadalafil in additional products labeled as Green Lumber, prompting a consumer alert about potential counterfeit products. Consumers have been discouraged from purchasing any Green Lumber products, not just those within the affected lot GL01.

Understanding Consumer Safety Outlets

The company has stated that consumer safety is their utmost priority, yet so far, they have not reported any adverse events linked to this recall. They plan to inform known buyers through email and ask for the return of the product instead of tossing it out—a step intended to manage quarantined and destroyed capsules in conjunction with the FDA.

The Importance of Awareness and Caution

For consumers, this recall underlines the importance of being vigilant regarding supplement safety, especially as many individuals may unknowingly mix products that shouldn't be combined. As a preventative measure, if you or someone you know uses Green Lumber products, now is the time to consult with a healthcare professional to assess any potential risks, especially regarding cardiovascular health.

What Can You Do?

If you’ve purchased the recalled capsules, ensure you follow up with Green Lumber for its return process. As consumers, being informed about the products we use is vital; take a moment to review labels and not just trust product claims or marketing. The risks associated with undeclared ingredients can be significant, and protecting yourself and your health should come first.

Trends

1 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
11.21.2026

Vietnam's Shocking Medical Case: A Tumor? No, It’s a Dracunculus Worm!

Update When a Tumor Turns Out to Be a Worm: A Startling DiscoveryIn a mind-boggling medical case reported in Vietnam, doctors opened a lump that they thought was a tumor, only to discover a live worm wriggling inside. The roundworm was identified as belonging to the genus Dracunculus, which includes the notorious guinea worm, once a rampant human parasite and currently considered nearly eradicated. This unusual incident highlights the complexities of parasitic infections in regions that were once thought to be free from such maladies.The Baffling Case of Tumor-like Dracunculus InfectionsInitially believed to be a soft-tissue tumor, the cyst—a cyst resembling a briskly growing lump—raised suspicion among medical professionals. Upon extraction, they found a live Dracunculus species worm, which, through genetic testing, has puzzled experts worldwide. According to the authors—Hai Nguyen Thi and Hong Anh Vu Thi—this case represents the first documented occurrence of a tumor-like presentation of human dracunculiasis in Vietnam. With Vietnam being certified free of guinea worm disease since 1998, this unexpected resurgence of a parasite adds a perplexing twist to the country's health landscape.Unraveling the Guinea Worm's MystiqueClassic presentations of guinea worm disease follow a pretty straightforward pattern: individuals ingest larvae found in contaminated water supply, leading to emerging worms that push through the skin to cause painful blisters. This particular case, however, challenges that narrative. The worm stayed enclosed in a cyst reminiscent of a tumor, complicating its diagnosis where infections are rare, as noted by the researchers.The Growing Challenge of Dracunculus Infections in VietnamAs of 2025, a significant number of cases—24 reported infections across five northern provinces—have surfaced. Health officials have linked these infections to the consumption of undercooked fish, snakes, and drinking untreated water, suggesting a different transmission pathway than previously assumed. This raises concerns about the possible resurgence of a parasite long thought to be eliminated from the region, revealing a public health challenge that the local healthcare system is currently unprepared for.Global Perspectives: A Race Against TimeWhile the global eradication campaign led by the Carter Center reported only a handful of guinea worm cases in 2025, Vietnam's rise in infections is alarming. The intricate relationship between local dietary habits and the newly emerging infections may suggest a need for educational campaigns focused on food safety and hygiene in conjunction with environmental health measures. Enhanced public awareness could be key to preventing further transmission.This discovery in Vietnam opens the door to many questions that experts must address, particularly regarding the specific species of Dracunculus involved in these recent infections. Accurate identification is crucial for effective prevention and eradication strategies, as many related species do not follow the same routes of transmission. Without understanding how these parasites interact with the local ecosystem and human behavior, efforts to eliminate them may fall short.

11.20.2026

Malaria Beyond Blood Tests: A Surprising Heart Complication Discovery

Update The Hidden Danger of Malaria: When Tests FailIn an intriguing case outside the usual narrative of malaria, a Nigerian man in his 70s was fortunate to receive a diagnosis that offered a rare glimpse into the often-overlooked complexities of the parasite’s behavior. While malaria is predominantly regarded as a blood disease, this case emphasized how it can manifest in unexpected forms—in this instance, as fluid accumulation around the heart. The man had traveled to Canada, where, after weeks of undiagnosed symptoms, he was admitted to the hospital. Tests for malaria returned negative, however, several weeks later, a genetic examination of pericardial fluid revealed the presence of Plasmodium falciparum, the deadliest malaria parasite.This scenario paints a sobering picture of the potential pitfalls in diagnosing malaria, especially when the symptoms are more reminiscent of cardiac distress than typical malaria signs like fever. Despite the initial negative blood tests and a progression of symptoms that would lead most doctors to rule out malaria, the genetic evidence ultimately pointed toward a potential cardiac complication linked with the infection.Why Think Beyond the Norm?Understanding the expansive impact of malaria on cardiovascular health is crucial. Although the main focus tends to be on the blood, studies show that up to 9.7% of malaria cases can present with pericardial effusion, as noted by the authors of the recent case study and corroborated by similar research across different populations. Highlighting cardiovascular implications broadens the conversation around malaria and emphasizes the need for comprehensive examinations beyond the standard blood tests.Awareness and Action: The Real Game ChangerAs healthcare professionals are often trained to look for preventable conditions and treatable illnesses, an expanded understanding of malaria's reach could prompt better patient care strategies. Early diagnosis can lead to timely interventions, but this requires a better understanding of the array of symptoms associated with the disease. Cases such as this stress the need for doctors to consider a full cardiac assessment in patients exhibiting unusual symptoms or failure to respond to routine malaria treatments.Future Directions: What Lies Ahead?Looking forward, the need for research into cardiovascular complications related to malaria is critical. The existing data indicates an underinvestment in this area, with many healthcare professionals unaware of the cardiovascular risks tied to malaria infection. With malaria continuing to impact millions worldwide, it’s essential for this knowledge to permeate standard medical training and practice.A Call for Comprehensive TestingThe case serves as a reminder that the medical community must remain vigilant and progressive in their approach to diagnosing diseases like malaria. Standard protocols do not capture every scenario, and healthcare providers should be encouraged to remain open-minded about potential atypical presentations of well-established diseases. A more inquisitive approach could save lives, especially when diseases intersect with other bodily systems.The journey for the Nigerian man was perilous, marked by multiple misdiagnoses before the true culprit was identified. His experience highlights the critical importance of updated medical training and practices that adapt to the changing landscape of infectious diseases. With 250 million malaria cases recorded globally, the time for enhanced awareness and diagnostic acuity is now.

11.19.2026

Gazyva's FDA Approval: A New Hope for Primary Membranous Nephropathy Patients

Update Gazyva's Groundbreaking Approval: A Game Changer for Rare Kidney Disease Treatment The recent FDA approval of Gazyva, or obinutuzumab, marks a significant milestone for patients battling primary membranous nephropathy, a rare autoimmune disease that silently threatens kidney function. This is not just a triumph for pharmaceutical innovation but a beacon of hope for the approximately 96,000 Americans who live with this debilitating condition. A Rare But Serious Condition In primary membranous nephropathy, the immune system mistakenly attacks the kidney's glomeruli—tiny filters necessary for waste removal. This dysfunction leads to severe complications such as high cholesterol, high blood pressure, and in extreme cases, kidney failure. Fatigued and overwhelmed, many patients are faced with grim choices like dialysis or transplantation if left untreated. It's critical to note that approximately 30% of untreated patients may progress to kidney failure within ten years, emphasizing the urgency for effective treatments. Gazyva's Mechanism: A Targeted Approach Developed by Genentech, Gazyva is an antibody that specifically targets CD20, a protein found on certain immune cells known as B cells. These cells produce antibodies that can exacerbate the disease. While Gazyva has seen past use in treating certain cancers and lupus nephritis, its new approval for primary membranous nephropathy sets a precedent, as it’s the first drug explicitly designed for this condition. The FDA not only recognized Gazyva’s efficacy but also granted it Breakthrough Therapy and Orphan Drug designations, highlighting the pressing need for more accessible treatments for rare diseases. The MAJESTY Trial: Promising Results The approval was anchored on the promising results of the MAJESTY trial—a phase 3 clinical trial with 142 adult participants. The study demonstrated that patients receiving Gazyva achieved complete remission at significantly higher rates (36%) compared to those treated with tacrolimus (6%). This difference of 31 percentage points is not merely statistical; it represents a tangible improvement in the quality of life for patients suffering from this chronic illness. What Comes Next? Challenges and Side Effects While the approval is promising, it is accompanied by significant warnings, including potential reactivation of hepatitis B and a rare brain infection known as progressive multifocal leukoencephalopathy. This highlights the need for thorough patient screening and ongoing monitoring. The most commonly reported side effects included infusion-related reactions and upper respiratory infections—common concerns that require attention but also reflect the importance of continuous patient education about their treatment journeys. The Bigger Picture: Accessing Care With an approved treatment now available, discussions around healthcare coverage and access to Gazyva are paramount. Insurance companies may be more inclined to cover an FDA-approved drug than off-label treatments, which could significantly impact the financial burden on patients and families affected by this disease. This approval opens up new avenues of conversation between healthcare providers, patients, and insurers, fostering hope not only for better health outcomes but also for more inclusive healthcare policies. Conclusion: A New Hope for Patients The approval of Gazyva introduces a new chapter in the fight against primary membranous nephropathy, showcasing the ongoing need for targeted therapies tailored to rare diseases. As we venture forward, the collective responsibility lies in ensuring that patients not only have access to this groundbreaking treatment but also receive the comprehensive support they require. For those directly affected, understanding this new option could spell the difference between hope and despair.

Pulse On Wellcare

Our mission is to bridge the gap between healthcare and wellness, providing a comprehensive media destination for those seeking reliable information and inspiration from sponsor content.

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

864-571-8644

AVAILABLE FROM 8AM - 5PM

Regional News

Southwest 

ABOUT US

We are dedicated to empowering individuals across all 50 states in their journey toward healthier living.

© 2026 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*